Shares of KalVista Pharmaceuticals, Inc. (KALV) are rising more than 17% Tuesday morning.
The company today said it has entered into a subscription agreement with institutional investors to sell 9.484 million shares in a registered direct offering at a price of $6.00 per share and 182,470 prefunded warrants at $5.999.
Gross proceeds from the offering, which is expected to close on December 28, is about $58 million.
The company plans to use the net proceeds to fund its clinical trials, commercial sales development, and research among other things.
KALV is at $5.98 currently. It has traded in the range of $4.12-$17.34 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.